Search Results for “EC” – Page 144 – media

Security Fears Outweigh Benefits in Mobile Device Management Report

A global survey of healthcare executives finds significant satisfaction in mobile device programs, but a lack of faith in mHealth security.
- Source: mHealthIntelligence
- 483
- April 13, 2018
digital health Market Views mHealth
Portable Cancer-Detecting Device Being Developed By Korean Startup

To diagnose cancer, doctors use a bunch of complex examinations like an MRI, a CT scan, a biopsy or a lengthy blood test. Because of the sophisticated machines and equipment needed for these techniques and procedures, they are only conducted in the hospital setting. One startup is about to change this with its portable cancer-detecting device.
- Source: International Business Times
- 1,957
- April 13, 2018
cancer medical device Researches
FDA approves first AI-powered device to detect diabetic retinopathy

The FDA today approved the first medical device to harness artificial intelligence for the detection of diabetic retinopathy in adults who have diabetes.
- Source: Drug Delivery Business News
- 671
- April 13, 2018
AI FDA New Approvals
Strong Growth Potential in Global Clinical Trial Data Management and eClinical Solutions Market to Cross $4 Billion by 2020

Unified cloud-based eClinical platforms, with built-in scalability and modularity, will drive growth opportunities across the globe
- Source: PR Newswire
- 681
- April 12, 2018
Clinical Trial Market Views mHealth
Ionis and AstraZeneca Advance New Drug for NASH

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today announced that it has licensed IONIS-AZ6-2.5-LRx, or AZD2693, to AstraZeneca (NYSE: AZN) following advancement of the drug into development. IONIS-AZ6-2.5-LRx is designed to inhibit an undisclosed target to treat patients with nonalcoholic steatohepatitis (NASH)
- Source: Prnewswire
- 621
- April 11, 2018
Market Views NASH
FDA Approves Rucaparib for Maintenance Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

On April 6, 2018, the Food and Drug Administration(FDA) approved rucaparib (Rubraca®, Clovis Oncology Inc.), a poly ADP-ribose polymerase (PARP) inhibitor, for the maintenance treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.
- Source: asco.org
- 532
- April 11, 2018
FDA New Approvals rucaparib
U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb’s Application for Opdivo (nivolumab) in Previously Treated dMMR or MSI-H Metastatic Colorectal Cancer

Application based on results from Phase 2 CheckMate -142 study
- Source: investors.bms
- 606
- April 11, 2018
Bristol-Myers Squibb FDA New Approvals Opdivo
Ferring Acquires Innovative Biotechnology Company and Microbiome Pioneer Rebiotix Inc.

Ferring Pharmaceuticals* and Rebiotix Inc. today announce that they have agreed to the acquisition of Rebiotix by Ferring. This acquisition brings together two innovative healthcare companies that share a common commitment to exploring and understanding the human microbiome to develop new solutions for patients.
- Source: Businesswire;
- 593
- April 9, 2018
acquisition CDI Market Views non-antibiotic
This DARPA-Developed Brain Implant Can Help Recover Your Memories

No longer science fiction, a "prosthetic memory" neural implant can actually improve short term memories.
- Source: Popular Mechanics
- 714
- April 9, 2018
brain medical device Researches
Rejection–FDA Issues CLRs for Two Celltrion and Teva Biosimilars

The U.S. Food and Drug Administration (FDA) issued two Complete Response Letters (CRLs) to South Korean manufacturer Celltrion. One was for a proposed biosimilar for Genentech and Biogen’s Rituxan for lymphomas and leukemias, and a proposed biosimilar to AbbVie’s Humira for rheumatoid arthritis, plaque psoriasis, Crohn’s disease and other autoimmune disorders.
- Source: biospace
- 640
- April 9, 2018
AbbVie biosimilar FDA Genentech

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.